‘Small Biotech Exception’ From Medicare Price Negotiation Granted To Four Drugs For 2026

CMS has not disclosed how many requests for the exception it received but will follow up with applicants regarding its decisions this month.

lab research
CMS Criteria For Decisions On Applications Still To Come • Source: Shutterstock

The Centers for Medicare and Medicaid Services excused four drugs from being selected for Medicare price negotiation in the first round because they qualified for the small biotech exception, according to the agency.

“For initial price applicability year 2026, drug companies submitted requests and information to CMS for four drugs that were determined...

More from Market Access

More from Pink Sheet